Bruker Corporation (BRKR) Income Statement Analysis

See more : North Copper (Shanxi) Co., Ltd. (000737.SZ) Income Statement Analysis – Financial Results

Complete financial analysis of Bruker Corporation (BRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bruker Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

Bruker Corporation (BRKR)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.bruker.com

About Bruker Corporation

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	2.96B	2.53B	2.42B	1.99B	2.07B	1.90B	1.77B	1.61B	1.62B	1.81B	1.84B	1.79B	1.65B	1.30B	1.11B	1.11B	547.58M	435.83M	297.57M	284.42M	260.68M	116.37M	92.69M	76.60M	64.69M	42.21M
Cost of Revenue	1.45B	1.23B	1.21B	1.05B	1.08B	995.60M	952.90M	868.80M	915.20M	1.05B	1.03B	960.00M	899.20M	698.90M	595.90M	602.10M	294.44M	236.50M	171.76M	165.94M	144.83M	55.87M	43.59M	35.59M	28.13M	0.00
Gross Profit	1.51B	1.31B	1.21B	939.80M	995.30M	900.00M	813.00M	742.50M	708.60M	763.30M	805.20M	831.40M	752.50M	606.00M	518.60M	505.00M	253.14M	199.33M	125.81M	118.48M	115.85M	60.50M	49.10M	41.02M	36.56M	42.21M
Gross Profit Ratio	51.05%	51.59%	50.03%	47.29%	48.02%	47.48%	46.04%	46.08%	43.64%	42.20%	43.78%	46.41%	45.56%	46.44%	46.53%	45.61%	46.23%	45.74%	42.28%	41.66%	44.44%	51.99%	52.97%	53.54%	56.51%	100.00%
Research & Development	294.80M	235.90M	220.80M	198.00M	187.70M	173.40M	162.70M	149.00M	145.70M	174.20M	190.50M	195.30M	177.20M	141.40M	126.40M	133.80M	58.47M	49.96M	41.36M	43.22M	38.03M	20.73M	18.47M	20.03M	15.14M	0.00
General & Administrative	730.10M	610.80M	564.50M	477.80M	500.20M	444.70M	415.90M	390.50M	392.20M	451.00M	437.90M	442.40M	406.60M	303.10M	69.50M	254.50M	140.04M	112.99M	73.81M	76.38M	77.76M	33.82M	27.72M	20.25M	14.76M	0.00
Selling & Marketing	0.00	-3.40M	-3.30M	-9.20M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.00M	-5.80M	185.80M	183.80M	105.98M	84.01M	51.44M	55.98M	60.42M	26.81M	21.71M	0.00	0.00	0.00
SG&A	730.10M	607.40M	561.20M	468.60M	500.20M	444.70M	415.90M	390.50M	392.20M	451.00M	437.90M	442.40M	403.60M	297.30M	255.30M	254.50M	140.04M	112.99M	73.81M	76.38M	77.76M	33.82M	27.72M	20.25M	14.76M	0.00
Other Expenses	52.20M	-29.70M	-14.30M	-24.90M	-6.50M	-19.50M	-19.70M	-25.80M	-20.40M	-21.20M	-28.60M	-13.90M	13.10M	5.80M	200.00K	8.50M	4.66M	5.72M	0.00	0.00	9.75M	202.00K	-356.00K	0.00	3.49M	42.37M
Operating Expenses	1.08B	843.30M	782.00M	666.60M	687.90M	618.10M	578.60M	539.50M	537.90M	625.20M	628.40M	637.70M	596.90M	450.30M	255.30M	388.30M	198.51M	162.95M	115.17M	119.59M	125.53M	54.75M	45.83M	40.28M	33.38M	42.37M
Cost & Expenses	2.53B	2.07B	1.99B	1.71B	1.77B	1.61B	1.53B	1.41B	1.45B	1.67B	1.66B	1.60B	1.50B	1.15B	851.20M	990.40M	492.95M	399.45M	286.93M	285.53M	270.36M	110.62M	89.42M	75.87M	61.51M	42.37M
Interest Income	11.20M	4.10M	900.00K	3.20M	1.30M	1.20M	800.00K	300.00K	1.20M	800.00K	1.00M	900.00K	1.00M	900.00K	1.00M	4.90M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	16.40M	16.10M	14.30M	14.40M	16.00M	12.60M	15.40M	13.20M	13.00M	13.30M	13.40M	14.30M	7.30M	5.60M	7.50M	40.50M	11.84M	3.96M	0.00	3.85M	6.36M	20.15M	0.00	0.00	1.35M	0.00
Depreciation & Amortization	114.90M	88.80M	89.20M	80.50M	75.60M	64.90M	63.90M	54.30M	53.30M	59.70M	61.30M	59.10M	3.00M	5.80M	29.70M	29.90M	12.63M	13.29M	8.61M	9.79M	16.87M	8.20M	6.04M	4.15M	3.49M	0.00
EBITDA	599.00M	545.30M	497.10M	320.70M	380.00M	340.10M	299.50M	262.10M	235.90M	215.60M	239.10M	211.70M	205.70M	155.70M	166.30M	134.80M	63.07M	49.87M	19.25M	8.68M	697.00K	17.47M	10.30M	4.88M	6.66M	-161.00K
EBITDA Ratio	20.21%	21.75%	21.37%	17.79%	18.48%	18.29%	16.89%	15.97%	14.08%	11.57%	12.94%	12.14%	9.60%	12.38%	35.67%	14.75%	13.29%	11.85%	6.47%	3.05%	5.91%	20.80%	9.68%	6.64%	10.93%	-0.38%
Operating Income	436.90M	432.70M	413.30M	248.30M	300.90M	262.40M	214.70M	177.20M	145.70M	105.40M	148.20M	156.00M	155.60M	155.70M	136.70M	108.20M	49.97M	30.66M	10.64M	-1.12M	-9.68M	5.75M	3.27M	734.00K	3.18M	-161.00K
Operating Income Ratio	14.74%	17.10%	17.09%	12.49%	14.52%	13.84%	12.16%	11.00%	8.97%	5.83%	8.06%	8.71%	9.42%	11.93%	12.27%	9.77%	9.13%	7.04%	3.57%	-0.39%	-3.71%	4.94%	3.53%	0.96%	4.91%	-0.38%
Total Other Income/Expenses	107.30M	-18.80M	-19.70M	-22.50M	-20.50M	-17.70M	-21.70M	-4.20M	-17.70M	-4.10M	-23.60M	-17.70M	-10.10M	-5.60M	-7.60M	-15.00M	-89.09M	3.76M	-780.00K	-3.78M	1.85M	-9.88M	2.73M	1.59M	-1.32M	161.00K
Income Before Tax	544.20M	413.90M	393.60M	225.80M	280.40M	244.70M	197.80M	177.60M	128.00M	101.30M	124.60M	138.30M	145.50M	150.10M	129.10M	93.20M	48.61M	34.42M	11.95M	-4.90M	-7.83M	-4.14M	6.01M	2.32M	1.86M	0.00
Income Before Tax Ratio	18.36%	16.36%	16.28%	11.36%	13.53%	12.91%	11.20%	11.02%	7.88%	5.60%	6.77%	7.72%	8.81%	11.50%	11.58%	8.42%	8.88%	7.90%	4.02%	-1.72%	-3.00%	-3.56%	6.48%	3.03%	2.88%	0.00%
Income Tax Expense	117.70M	116.40M	113.00M	64.40M	82.40M	63.70M	117.50M	23.10M	23.10M	41.70M	42.80M	60.10M	51.50M	53.30M	48.10M	28.00M	16.78M	15.93M	8.26M	2.87M	9.72M	2.06M	2.37M	254.00K	986.89K	0.00
Net Income	427.20M	296.60M	277.10M	157.80M	197.20M	179.70M	78.60M	153.60M	101.60M	56.70M	80.10M	77.50M	92.30M	95.40M	81.20M	64.90M	31.53M	18.48M	3.65M	-7.83M	-17.55M	-6.20M	3.64M	2.25M	1.25M	0.00
Net Income Ratio	14.41%	11.72%	11.46%	7.94%	9.51%	9.48%	4.45%	9.53%	6.26%	3.13%	4.35%	4.33%	5.59%	7.31%	7.29%	5.86%	5.76%	4.24%	1.23%	-2.75%	-6.73%	-5.33%	3.92%	2.94%	1.93%	0.00%
EPS	2.92	2.00	1.83	1.03	1.27	1.15	0.50	0.95	0.60	0.34	0.48	0.47	0.56	0.58	0.50	0.40	0.61	0.18	0.10	-0.08	-0.17	-0.12	-0.05	0.04	0.03	0.00
EPS Diluted	2.90	1.99	1.81	1.02	1.26	1.14	0.49	0.95	0.60	0.33	0.48	0.46	0.55	0.58	0.49	0.39	0.60	0.18	0.10	-0.08	-0.17	-0.12	-0.05	0.04	0.03	0.00
Weighted Avg Shares Out	146.40M	148.60M	151.40M	153.40M	155.20M	156.20M	158.10M	161.40M	168.20M	167.80M	166.50M	166.00M	165.40M	164.40M	163.50M	162.70M	161.20M	101.51M	100.82M	96.38M	103.26M	52.60M	54.06M	56.25M	45.50M	45.50M
Weighted Avg Shares Out (Dil)	147.20M	149.40M	152.90M	154.60M	156.60M	157.20M	159.10M	162.20M	169.10M	169.50M	168.50M	167.40M	166.90M	165.70M	164.90M	165.60M	164.30M	102.56M	101.13M	96.38M	103.26M	52.60M	54.06M	56.25M	45.50M	45.50M

Bruker (NASDAQ:BRKR) Releases FY 2027 Earnings Guidance

May 20, 2024https://www.defenseworld.net

Bruker (NASDAQ:BRKR – Get Free Report) issued an update on its FY 2027 earnings guidance on Friday morning. The company provided EPS guidance of 4.000-4.300 for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion. Bruker Stock Performance...

Access Reminder for Bruker Investor Webinar on May 17, 2024

May 16, 2024businesswire.com

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) will host an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) tomorrow May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech,...

Bruker Announces Quarterly Dividend

May 15, 2024businesswire.com

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid...

2 Instruments Stocks to Watch From a Prospering Industry

May 14, 2024zacks.com

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.

Investing in Bruker (BRKR)? Don't Miss Assessing Its International Revenue Trends

May 13, 2024zacks.com

Examine Bruker's (BRKR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Shhh! 3 Secret Nanotech Stocks Flying Below Wall Street's Radar

May 10, 2024investorplace.com

The world of nanotechnology relies on the mastery of the molecular scale. Thus, companies that thrive on the production of materials and chemical interactions at the atomic level could someday hold the keys to our economic future.

German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win to NanoString and Bruker

May 7, 2024businesswire.com

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the “928 Patent”) in Germany (case 3 Ni 20/22)....

Bruker Completes Asset Acquisition of NanoString Business

May 6, 2024businesswire.com

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that it has closed its asset acquisition of the business of NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of life-science research solutions for spatial transcriptomics and gene...

Down -22.53% in 4 Weeks, Here's Why Bruker (BRKR) Looks Ripe for a Turnaround

May 6, 2024zacks.com

Bruker (BRKR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.